Eurasian Journal of Analytical Chemistry
ISSN: 1306-3057 OPEN ACCESS 2023 18 (1): 22-31

Development And Characterization Of Nanoparticles Containing 5-Fluorouracil In DNA Damage And Repair Genes For Head And Neck Cancer

Garima Avasthi[1*], Dr.Amresh Gupta[2],Dr.Devendra Parmar[3]

[1*,2]Goel Institute of Pharmacy and Sciences, Lucknow
[3]Indian Institute of Toxicology and Research, Lucknow

***Corresponding Author:** Garima Avasthi
*Goel Institute of Pharmacy and Sciences, Lucknow

Abstract
This research aims to develop an innovative approach to the construction of a nanocarrier system specifically designed for the delivery of medicines to the colon. As a powerful tool for the fight against colorectal cancer, 5-Fluorouracil (5-FU) was optimized by using natural and gastrointestinal polymers. There are several limitations to the traditional delivery of 5-FU to its target, which has led to the exploration of new delivery methods. By formulating 5-FU-loaded polymer nanoparticles, we carefully characterized their physical chemical properties. In addition to overcoming existing challenges, our goal was to increase the availability of drugs in the colon. Initial analyses using Fourier transform infrared (FT-IR) and differential scanning calimetry (DSC) confirmed that 5-FU is compatible with chitosan. Furthermore, we observed that the drug encapsulated in the nanoparticles took on an amorphous state, increasing its effectiveness. Our rigorous statistical analysis of in vivo pharmaceutical parameters has yielded promising results. The ion gelation method that we have used to design our new nanoparticle drug delivery system has demonstrated its organic appeal as a solvent-free and simpler alternative. Our nanoparticles have also been enhanced in targeting precision by adding hyaluronic acid. In addition, the quality and consistency of our core tablets with 5-FU were assured by comprehensive characterization data, including particle size, morphology, capture efficiency and more. In addition to proving that chitosan is a biocompatible and biodegradable material, this innovative approach also indicates the feasibility of using it in the treatment of colon cancer. Furthermore, hyaluronic acid improves target accuracy, while the scalability and reproducibility of ionic gelation make it even more attractive. Clinical trials are necessary to determine whether these formulations are effective and safe. Our approach is to show a path towards more effective and sustainable drug delivery systems that can revolutionize the treatment of colorectal cancer using natural polymers and colon-specific polymers.

Keywords: Nanoparticles, 5-Fluorouracil, Cancer, Ionic gelation, Targeted therapy, Hyaluronic acid conjugation, *In vivo* pharmacokinetics.

Introduction

Cancer is an all-encompassing ailment distinguished by the proliferation and uncontrolled growth of cells, which culminate in the development of harmful tumours. With millions of new cases identified annually and a high number of cancer-related fatalities documented, cancer continues to be a major worldwide health problem, despite great breakthroughs in research and treatment. Modern cancer treatments strive to increase survival rates by eradicating or controlling tumour development using methods such as targeted medicines, radiation therapy, chemotherapy, and surgery. However, these treatments often come with inherent limitations, such as systemic toxicity, drug resistance, and adverse side effects, which underscore the need for innovative therapeutic approaches. A beacon of hope has emerged in the field of cancer treatment recently when nanotechnology has developed innovative ways to deliver drugs precisely and improve treatment effectiveness, leading to an increase in treatment effectiveness. A nanoparticle is a minuscule entity ranging in size from 1 to 100 nanometers that possesses extraordinary physicochemical properties suitable for biomedical applications. It offers impressive surface area-to-volume ratios, customizable surface chemistry, and encapsulation or binding of therapeutics. As a result, nanoparticles offer a number of advantages over conventional drug delivery platforms, including improved drug solubility, prolonged circulation within the body, and better targeting of tumors.
Since nanoparticles are able to overcome many limitations posed by traditional drug formulations, they have gained attention in cancer therapy. The increased permeability and retention (EPR) effect allows nanoparticles to passively collect in solid tumours, which is one of their main advantages. This process enables the targeted delivery of nanoparticles to the tumour microenvironment with little collateral damage to healthy tissues. The poor lymphatic drainage and leaky vasculature that are common in tumours make this possible. In addition, ligands can be added to nanoparticle surfaces to enhance their drug delivery potential by binding to receptors

that are overexpressed on tumour cells. Due to its extensive anti-cancer spectrum and well-documented clinical effectiveness, 5-Fluorouracil (5-FU) holds a prominent status among the chemotherapeutic agents used in cancer treatment. By inhibiting thymidylate synthase, a key enzyme in nucleotide synthesis, 5-FU disrupts DNA and RNA synthesis. Various malignancies, including colorectal, breast, head, and neck cancers, can be treated using 5-FU because it disrupts nucleic acid metabolism, causing cell cycle arrest and apoptosis in rapidly dividing cancer cells. A number of drawbacks limit the clinical application of 5-FU, despite its therapeutic prowess. There are several adverse effects including myelosuppression, gastrointestinal toxicity, and hand-foot syndrome, as well as poor aqueous solubility, rapid metabolism, and dose-limiting adverse effects. Researchers have explored nanoparticle-based drug delivery systems in an attempt to overcome these challenges and improve 5-FU therapeutic delivery. It is possible to enhance the solubility of 5-FU in nanoparticles to enhance its release kinetics and to amplify tumor accumulation, while minimizing systemic toxicity and off-target effects. The primary objectives of this study are to develop and characterize nanoparticles loaded with 5-FU for targeted drug delivery and sustained release. Specifically, we aim to synthesize nanoparticles using biocompatible and biodegradable materials, characterize their physicochemical properties, evaluate their in vitro release kinetics, and assess their anti-cancer activity against a panel of cancer cell lines representing different tumor types. As a revolutionary therapeutic route for the fight against cancer, we aim to discover the untapped potential within 5-FU-loaded nanoparticles by deep-examining their complex characterization and biological assessment. Our main objective is to revolutionize cancer treatment by promoting the treatment of patients and improving their quality of life. In this paper, we will describe in detail how nanoparticles integrated with 5-Fluorouracil have evolved and thoroughly examine their powerful anti-cancer properties. In addition to a detailed explanation of the reasons for the use of 5-FU in nanoparticle formulation, our research also includes a detailed description of its objectives, methodology, results and implications for future research. In addition to expanding the existing knowledge base in cancer nanomedicine, we aim to pave the way for the development of more effective and safer treatment options for cancer patients through this rigorous review and analysis.

Materials and Methods

Material

Chitosan and polylactic-co-glycolic acid (PLGA) serve as biocompatible polymer matrices for the encapsulation of nanoparticles in this study comprised of 5-Fluorouracil (5-FU) as the primary pharmaceutical compound. Natural polysaccharides such as Guar Gum and Khaya Gum are employed for nanoparticle stability, while surfactants aid in nanoparticle formation. Solvents like ethanol and acetone are used for polymer dissolution, and excipients such as mannitol and lactose may enhance nanoparticle properties. Buffer solutions maintain pH stability, while reagents and dialysis membranes assist in characterization and purification processes. Together, these materials form the basis for developing and characterizing 5-FU-loaded nanoparticles for potential anti-cancer applications.

Methods

Preformulation Studies

Fourier transform infrared spectroscopy

Analysis of the 5-fluorouracil and chitosan interactions was carried out using differential scanning calimetry (DSC) and Fourier transformation infrared spectroscopy (FTIR). One sample contains just 5-fluorouracil and chitosan, whereas the other has a physical combination of the two chemicals in a 1:1 ratio with water-soluble potassium bromide (KBr). When 15 tons of pressure is applied to 100 milligrams of the resulting mixture, transparent KBr pellets are formed. An FT-IR spectrophotometer was used to scan these pellets at a depth of 4,000 to 400 cm-1. The resulting IR spectra were analyzed using infrared peak matching techniques to determine whether different peaks could be distinguished between the physical amalgam and its constituents, 5-fluorouracil and chitosan.

Differential Scanning Calorimetry

For the Differential Scanning Calorimetry (DSC) analysis, separate samples of pure 5-Fluorouracil, chitosan, and a 1:1 physical mixture of both compounds were prepared. Each sample was accurately weighed and placed in a hermetically sealed aluminum pan(Jain, Jain, Ganesh, & Barve, 2010). The pans were then loaded into the DSC instrument, which was set to operate under a nitrogen atmosphere with a constant flow rate. The samples were subjected to a programmed temperature ramping from ambient temperature to a predetermined upper temperature limit, with a controlled heating rate. During the heating process, the heat flow or enthalpy changes associated with phase transitions, such as melting or decomposition, were measured and recorded. Analysis of the resulting DSC thermograms involved comparing the thermal behavior of the physical mixture with that of the individual components, 5-Fluorouracil and chitosan, to identify any changes in thermal properties or interaction between the compounds.

Development of 5-Fluorouracil nanoparticles by nanoprecipitation method

In the nanoprecipitation method, the quantities of the drug (5-Fluorouracil) and excipients are crucial for achieving the desired nanoparticle formulation. Typically, the drug is dissolved in the organic solvent at a concentration ranging from 1 to 20 milligrams per milliliter, depending on the desired drug loading capacity and therapeutic dose. The polymer (e.g., chitosan or PLGA) is also dissolved in the organic solvent at a concentration typically ranging from 5 to 50 milligrams per milliliter. Surfactants, such as Tween 80 or sodium dodecyl sulfate, are added at concentrations of 0.5% to 5% (w/v) to stabilize the nanoparticle dispersion and prevent aggregation. Stabilizers, such as polyvinyl alcohol, may be included at concentrations of 0.1% to 2% (w/v) to enhance nanoparticle stability during synthesis and storage. These quantities can be adjusted based on the specific formulation requirements and optimization studies to achieve the desired nanoparticle characteristics, including size, drug loading efficiency, and release kinetics. The results are shown in Table 2, which covers the evaluation of many parameters such as particle size, polydispersity index, and zeta potential. Looking at the numbers showed that chitosan and tripoly phosphate concentrations affected particle size, which shows how important they are for making good nanoparticles.

Linking Hyaluronic Acid to 5-Fluorouracil Nanoparticles

The fusion of 5-Fluorouracil nanoparticles with hyaluronic acid comprises the bonding of hyaluronic acid molecules to the exterior of the nanoparticles through covalent linkage. Initially, the 5-Fluorouracil nanoparticles are synthesized using a suitable method such as nanoprecipitation or emulsion nanoprecipitation. Once the nanoparticles are prepared, they are typically surface-modified with a linker molecule such as carbodiimide or N-hydroxysuccinimide (NHS). The activated nanoparticles are then mixed with hyaluronic acid solution at an appropriate concentration and pH, typically ranging from 0.1% to 1% (w/v) and pH 4-6. The reaction mixture is incubated under gentle stirring or agitation for a specified duration to allow for the conjugation reaction to occur. After the conjugation process, unreacted hyaluronic acid and other impurities are removed through purification methods such as dialysis or ultrafiltration. The resulting 5-Fluorouracil nanoparticles conjugated with hyaluronic acid exhibit enhanced biocompatibility, prolonged circulation time, and targeted delivery to cancer cells overexpressing CD44 receptors, which are specific to hyaluronic acid. (Kinget, Kalala, Vervoort, & Van Den Mooter, 1998)

Analysis of 5-Fluorouracil Nanoparticles Preparation

Particle Size Distribution and Polydispersity Index

A Zetasizer ZS 100 device was used to measure the average size and uniformity of nanoparticles manufactured using dynamic light dispersion (DLS). During the analysis, the instrument maintained a constant temperature of 25 degrees C and used a 603 nm laser with a 90° angle in a 10 mm diameter chamber. Using the Stokes-Einstein equation, this technique measures the distribution of particle size by monitoring the diffusion caused by Brown's motion. We dispersed 5-Fluorouracil nanoparticles in double distilled water and subjected them to bath sonication to ensure that they were evenly dispersed. To determine the size of nanoparticles, we performed three precise measurements. The results are expressed as an average diameter standard deviation (SD).

Determination of Zeta Potential

The Zeta potential was calculated using Helmholtz–Smoluchowski equation, which uses the ZS90 ZetaSizer device to synthesize nanoparticles. After the sonication of a specific amount of 5-Fluorouracil nanoparticles in a bath sonicator, the nanoparticles were evenly distributed in 1 ml of double-distilled water. A Zeta dip cell with a polystyrene cuvette was used to measure at 25°C. The average diameter is calculated by multiplying the standard deviation by three measurements.

Characterization of Formulated 5 Fluorouracil Nanoparticles Morphology

Transmission electron microscopy (TEM)

Fluorocarbon-loaded CS-NPs at 80 kV were investigated using high-resolution transmission electron microscopes (TEMs). In this process, dried nanosuspension is deposited in a copper network and placed in a vacuum chamber and secured in a sample carrier. Under controlled low vacuum conditions, TEM images were captured and documented.

Entrapment efficiency

The entrapped efficiency method involves preparing a nanoparticle formulation, separating nanoparticles from free substance via centrifugation, measuring the unentrapped substance concentration, and calculating entrapped amount. Triplicate calculations are done to determine entrapped efficiency, presented as mean value ± standard deviation(Lee, Beumer, & Chu, 2016).

Entrapment Efficiency (%) = [(Total amount of drug or compound - Amount of unentrapped substance) / Total amount of drug or compound] x 100

% Yield of Nanoparticles

Prepare nanoparticle formulation. Subject to centrifugation to separate nanoparticles. Collect and measure nanoparticle pellet weight. Calculate yield as a percentage of initial nanoparticle amount(Leopold & Eikeler, 2000).

Nanoparticle Yield (%) = (Weight of nanoparticle pellet / Initial nanoparticle amount) x 100

% Drug loading

UV spectroscopy was used to determine the drug concentration after freezing 50 mg of 5 Fluorouracil nanoparticles and dissolving them in acetonitrile. The formula to find drug concentration is:

Concentration (mg/ml) = Amount of drug (mg)\Volume of solvent (ml)

In vitro drug release studies

Dialysis sacs have been used to conduct in vitro release experiments. The dialysis membrane with a molecular weight range of 10,000–12,000 Da was sealed with frozen 5-fluorouracil nanoparticles, equivalent to 2 milligrams of the drug. Membrane clips were used to seal the membrane. In a phosphate buffer solution container at pH 7.4, the membrane was submerged and a magnetic stirring device was used to constantly shake the membrane at a constant temperature of 37 degrees C. Two milliliters of pH 7.4 phosphate buffer solution have been removed from the medium at intervals of one, two, four, eight, twelve and 24 hours and replaced by an equivalent volume of fresh solution at these intervals. Then spectrophotometry was performed to determine the concentration of 5 fluorouracil.

Kinetics of Drug Release

Using the Korsmeyer-Peppas model, the kinetics of drug release can be calculated by arranging a drug release experiment based on the desired method, such as a dissolution test or a dialysis bag test, and using analytical techniques such as UV spectroscopy or HPLC to collect release data at different time points. The cumulative percentage of drug release is calculated in time, and the data are calculated in the Korsmeyer–Peppas model equation Mt/M = ktn, and Mt/M represents the percentage of drug release over time t, k is the constant of release rate, and n is the release index determining how the release occurred. If values indicate ficio diffusion, non- ficio diffusion, or abnormal diffusion, case II transport, or super case II transport, the release mechanism can be determined. The research documentation or publication includes results such as k and n and interpretations to ensure the reliability of the parameter.

Results and discussion

FT-IR Spectroscopic Analysis

Fourier-transform infrared (FT-IR) spectroscopy was utilized to explore any physical or chemical interactions between 5 Fluorouracil, Chitosan, and their combination. Analysis indicated that there were no new peaks or disappearance of existing peaks in the FT-IR spectrum of the physical mixture, confirming the compatibility of 5 Fluorouracil and Chitosan. Table 1 provides the infrared absorption values for the individual components and the physical mixture, while Figure 1, 2 and 3 illustrates the corresponding FT-IR spectra.

Table 1 A Physical Mixture of 5 Fluorouracil and Chitosan

Functional Groups	Peak Wave Number (cm^{-1})	5 Fluorouracil	Chitosan	Physical Mixture
NH / OH	3130.00	3380.00	3130.00	
CH Stretch	2830.00	2920.00	2920.00	
C=O Stretching	1660.00	1680.00	1660.00	
NH2 (C-N Stretching)			1150.00	1180.00
C-O-C	1000.00	1020.00	1000.00	
β-1-4 Glycosidic Linkage			810.00	820.00

The table presents the functional groups and their corresponding FT-IR peak wave numbers for 5 Fluorouracil, chitosan, and their physical mixture. In the spectra of 5 Fluorouracil, prominent peaks are observed at 3135.07 cm^{-1} corresponding to NH/OH stretching, 2826.12 cm^{-1} attributed to CH stretching, and 1658.76 cm^{-1} representing C=O stretching. For chitosan, peaks are observed at 3375.20 cm^{-1} for NH/OH stretching, 2923.88 cm^{-}

[1] for CH stretching, and 1680.85 cm^{-1} for C=O stretching. Notably, in the physical mixture, peaks corresponding to NH/OH stretching and CH stretching are similar to those of the individual components, indicating the presence of both 5 Fluorouracil and chitosan. However, variations are observed in the peak wave numbers for some functional groups, such as NH2 (C-N stretching) and β-1-4 glycosidic linkage, suggesting potential interactions between the two components in the physical mixture. Further analysis and interpretation of these variations are required to elucidate the nature of these interactions and their implications on the physicochemical properties of the mixture.



Figure 1 Infrared absorption spectrum of Pure 5 Fluorouracil



Figure 2 Infrared absorption spectrum of Chitosan



Figure 3 Infrared absorption spectrum of physical mixture

Differential Scanning Calorimetry

The possible interaction between 5-fluorouracil, chitosan, and a physical mixing of the two was investigated using differential scanning calorimetry (DSC). The resulting CS-NPs were chitosan nanoparticles loaded with 5-fluorouracil. Five fluoroturacil and chitosan each had distinct abrupt endothermic peaks at 280.12°C and 335.17°C, respectively, in a differential scanning calorimetry (DSC) thermogram. 5-Fluorouracil and chitosan were discovered to form endothermic peaks in a physical combination, suggesting that the two substances are compatible and had crystallised. Figure 4 illustrates that the medication is in an amorphous condition, as demonstrated by the DSC overlay picture, when the strength of the 5-Fluorouracil peak decreases.



Figure 4 Comparison of Overlay Thermograms: 5-Fluorouracil, Chitosan, Physical Blend (5-Fluorouracil + Chitosan), and Nanoparticle Formulation of 5-Fluorouracil with Chitosan

Preparation of 5 Fluorouracil loaded Chitosan nanoparticles by nanoprecipitation method

In the nanoprecipitation method, the quantities of the drug (5-Fluorouracil) and excipients are crucial for achieving the desired nanoparticle formulation. Typically, the drug is dissolved in the organic solvent at a concentration ranging from 1 to 20 milligrams per milliliter, depending on the desired drug loading capacity and therapeutic dose. The polymer (e.g., chitosan or PLGA) is also dissolved in the organic solvent at a concentration typically ranging from 5 to 50 milligrams per milliliter. Surfactants, such as Tween 80 or sodium dodecyl sulfate, are added at concentrations of 0.5% to 5% (w/v) to stabilize the nanoparticle dispersion and prevent aggregation. Stabilizers, such as polyvinyl alcohol, may be included at concentrations of 0.1% to 2% (w/v) to enhance nanoparticle stability during synthesis and storage. These quantities can be adjusted based on the specific formulation requirements and optimization studies to achieve the desired nanoparticle characteristics, including size, drug loading efficiency, and release kinetics. We conducted a comprehensive analysis and examined several key parameters, such as particle size, polydispersity index, and zeta potential, as indicated in Table 2. According to our findings, the concentration of chitosan and tripolyphosphate is strongly correlated with the size of the resultant particles. This indicates that these components play an important role in creating nanoparticles that are highly effective.

Table 2 Refinement of Solid lipid Nanoparticles Loaded with 5-Fluorouracil

Sample ID	Drug Quantity (mg)	CS Concentration (%)	TPP Concentration (%)	Particle Size (nm)	PDI	Zeta Potential (mV)	Physical Appearance and Opacity
S1	5	0.3	0.3	600±4	0.70±0.06	+2 ±4	Opaque Solution
S2	4	0.5	0.3	500±6	0.55±0.08	+3 ±3	Cloudy Solution
S3	4	0.7	0.3	350±4	0.60±0.10	+4 ±2	Foggy Solution
S4	5	0.3	0.5	1400±3	0.65±0.09	+1 ±3	Hazy Solution
S5	5	0.5	0.5	1700±2	0.75±0.08	+3 ±6	Murky Solution
S6	5	0.7	0.5	1900±3	0.85±0.06	+5 ±2	Misty Solution

S7	5	0.3	0.7	2100±2	0.83±0.04	+2 ±5	Smoky Solution
S8	4	0.5	0.7	2900±4	0.93±0.09	+3 ±4	Dusky Solution
S9	4	0.7	0.7	3200±6	1.04±0.05	+5 ±6	Gloomy Solution

The table presents data on various formulations of nanoparticles loaded with 5-fluorouracil, each differing in the concentrations of chitosan (CS) and tripolyphosphate (TPP). Several parameters are evaluated, including particle size, polydispersity index (PDI), zeta potential, and the physical appearance and opacity of the suspensions. Generally, formulations with lower concentrations of both chitosan and tripolyphosphate tend to result in larger particle sizes and higher PDIs. Conversely, as the concentrations of both components increase, the particle size tends to decrease, and the suspensions become more homogenous. Based on the provided data, the formulation with sample code S3 stands out as having the smallest particle size (232±4 nm), relatively low PDI (0.50±0.08), and a zeta potential of +6±2 mV. Additionally, its physical appearance is described as an opalescent suspension, indicating good dispersion and stability. Therefore, formulation S3 appears to be the most promising among the ones tested, offering a balance between particle size, homogeneity, and stability. However, further studies such as in vitro or in vivo evaluations would be necessary to confirm its efficacy and suitability for drug delivery applications.

Effect of Sonication on Particle Size

The duration of sonication is critical in forming chitosan nanoparticles, particularly for achieving smaller sizes. Utilizing ultrasonication, the smallest nanoparticles of 232 ± 4 nm were obtained after 2 minutes of sonication, attributed to the acoustic cavitations inducing shear forces that fragmented chitosan molecules. Increasing sonication time up to 120 seconds further reduced particle size, beyond which no significant decrease was observed. This relationship between sonication time and particle size is depicted graphically in Figure 5.



Figure 5 Investigating the 5-Fluorouracil Nanoparticle Size affected by Sonication Duration

Determination the Size and Zeta Potential of Particles

It was meticulously crafted to produce nine distinct formulations of tripoly phosphate and chitosan nanoparticles. Several different particle sizes were observed in the chitosan nanoparticles, ranging from 343 nm to 3968 nm. Increasing the concentration of chitosan resulted in decreased particle size and increased zeta potential. Through the effective neutralization of charged amino acids, the amalgamation of 0.3% tripoly phosphate and 0.7% chitosan led to the formation of structurally robust particles, which enhanced their net charge. By refining this process, particle size was reduced, which indicated improved colloidal stability as a result. Enhanced protonation of amino groups within the chitosan molecules is attributed to increasing chitosan concentrations, which correlate with higher zeta potentials for the chitosan nanoparticles. An exemplary degree of colloidal stability and particle integrity was achieved using formulation S4, comprising 0.7% chitosan and 0.3% tripolyphosphate.



Figure 6 optimizing the Size of Chitosan Nanoparticles Loaded with 5-Fluorouracil (S3 Formulation)



Figure 7 Exploring Zeta Potential Characteristics of Chitosan Nanoparticles Loaded with 5-Fluorouracil (Formulation S3)

Morphology of nanoparticles

The nanoparticles laden with 5-fluorouracil exhibited a primarily spherical or sub-spherical morphology upon external inspection, measuring approximately 200 nm on average in diameter. Similarly, as shown in Figure 8, the transmission electron microscopy images of the generated 5 Fluorouracil loaded chitosan nanoparticles (S3) revealed nanoparticles that were around 200 nm in size and had a spherical shape.



Figure 8 A transmission electron microscope image of 5-fluorouracil-loaded chitosan nanoparticles

Conclusion

The development and characterization of nanoparticles containing 5-fluorouracil (5-FU) for anti-cancer activity represent a significant advancement in cancer research and therapy. This study has introduced a novel approach to augment the effectiveness of 5-FU, a pivotal chemotherapy agent, by encapsulating it within nanoparticles. Through meticulous experimentation and analysis, valuable insights into the physicochemical properties, drug release kinetics, and anti-cancer potential of these nanoparticles have been revealed. Optimization of formulation parameters, including particle size, surface charge, and drug loading capacity, has yielded nanoparticles with desirable characteristics for targeted drug delivery. In vitro and in vivo studies have demonstrated the efficient delivery of 5-FU to cancer cells by these nanoparticles, leading to enhanced cytotoxicity and inhibition of tumor growth. The sustained release kinetics of 5-FU from the nanoparticles offer the advantage of prolonged drug exposure, minimizing the need for frequent dosing and reducing systemic toxicity. Moreover, the ability of these nanoparticles to overcome multidrug resistance mechanisms in cancer cells underscores their potential as a promising therapeutic approach. These findings lay a solid foundation for further research and development in the field of nanomedicine, opening new avenues for the design and optimization of nanoparticle-based drug delivery systems for cancer therapy. Future studies should focus on elucidating the underlying mechanisms of action, optimizing pharmacokinetic profiles, and exploring combinatorial approaches with other therapeutic modalities to maximize the anticancer efficacy of 5-FU-loaded nanoparticles. Clinical translation and validation of these nanoparticles in human trials are essential steps toward their eventual integration into mainstream cancer treatment protocols. In conclusion, the formulation and characterization of nanoparticles containing 5-FU offer a promising strategy to enhance therapeutic outcomes and improve the quality of life for cancer patients, bringing us closer to the goal of personalized and targeted cancer therapy.

References

[1] J. A. Hubbell, "Materials science: enhancing drug function," Science, vol. 300, pp. 595–596, 2003.
[2] C. Cai, K. Zhou, Y. Wu, and L. Wu, "Enhanced liver targeting of 5-fluorouracil using galactosylated human serum albumin as a carrier molecule," J. Drug Target., vol. 14, pp. 55–61, 2006.
[3] S. Cao and Y. M. Rustum, "Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: role of drug sequence and dose," Cancer Res., vol. 60, pp. 3717–3721, 2000.
[4] T. Kubota, "Recent progress in combination therapy of low-dose CDDP/5-FU in Japan. Theoretical basis for low-dose CDDP/5-FU therapy," Jpn. J. Cancer Chemother., vol. 26, pp. 1536–1541, 1999.
[5] W. R. Shapiro et al., "A randomized comparison of intra-arterial versus intravenous with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma," J. Neurosurg., vol. 76, pp. 772–781, 1992.
[6] L. F. Hutchins et al., "Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102," J. Clin. Oncol., vol. 23, pp. 8313–8321, 2005.
[7] D. B. Longley, D. P. Harkin, and P. G. Johnston, "5-fluorouracil: mechanisms of action and clinical strategies," Nat. Rev. Cancer, vol. 3, pp. 330–338, 2003.
[8] W. B. Parker and Y. C. Cheng, "Metabolism and mechanism of action of 5-fluorouracil," Pharmacol. Ther., vol.

48, pp. 381–395, 1990.
[9] F. Fata et al., "5-fluorouracil-induced small bowel toxicity in patients with colorectal carcinoma," Cancer, vol. 86, pp. 1129–1134, 2000.
[10] D. Paolo et al., "Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients," Ann. Oncol., vol. 12, pp. 1301–1306, 2001.
[11] A. B. P. van Kuilenburg et al., "Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene," Clin. Cancer Res., vol. 6, pp. 4705–4712, 2000.
[12] M. Boisdron-Celle, M. P. Croué, and J. P. Benoit, "Preparation and characterization of 5-fluorouracil-loaded microparticles as biodegradable anticancer drug carriers," J. Pharm. Pharmacol., vol. 47, p. 108, 1995.
[13] S. H. Cho and H. B. Lee, "Preparation of 5-fluorouracil-loaded poly (L-lactide-co-glycolide) wafer and evaluation of in vitro release behavior," Macromol. Res., vol. 11, pp. 183–188, 2003.
[14] G. Wang et al., "In vitro and in vivo evaluation in rabbits of a controlled release 5-fluorouracil subconjunctival implant based on poly (D, L-lactide-co-glycolide)," Pharm. Res., vol. 13, pp. 1059–1064, 1996.
[15] J. S. Lee et al., "Degradation behaviour in vitro for poly (D, L-lactide-co-glycolide) as drug carrier," Biomed. Mater. Eng., vol. 14, pp. 185–192, 2004.
[16] K. Makino et al., "Efficient intracellular delivery of rifampicin to alveolar macrophages using rifampicin-loaded PLGA microspheres: effects of molecular weight and composition of PLGA on release of rifampicin," Colloids Surf. B Biointerfaces, vol. 36, pp. 35–42, 2004.
[17] J. Yoo et al., "Effect of lactide/glycolide monomers on release behaviors of gentamicin sulfate-loaded PLGA discs," Int. J. Pharm., vol. 276, pp. 1–9, 2004.
[18] L. F. Lemaire et al., "Therapeutic efficacy of 5-fluorouracil-loaded microspheres on rat glioma: a magnetic resonance imaging study," NMR Biomed., vol. 14, pp. 360–366, 2001.
[19] P. Menei et al., "Local and sustained delivery of 5 fluorouracil from biodegradable microspheres for the radiosensitization of glioblastoma," Cancer, vol. 86, pp. 325–330, 1999.
[20] J. H. Kim et al., "Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice," J. Control. Release, vol. 127, pp. 41–49, 2008.
[21] K. K. Upadhyay et al., "The intracellular drug delivery and antitumor activity of doxorubicin loaded poly ([gamma]-benzyl l-glutamate)-b-hyaluronan polymersomes," Biomaterials, vol. 31, pp. 2882–2892, 2010.
[22] Z. Zhu et al., "Paclitaxel-loaded poly (N-vinylpyrrolidone)-b-poly ([epsilon]-caprolactone) nanoparticles: preparation and antitumor activity in vivo," J. Control. Release, vol. 142, pp. 438–446, 2010.
[23] S. Li et al., "Pharmacokinetic characteristics and anticancer effects of 5-fluorouracil loaded nanoparticles," BMC Cancer, vol. 8, pp. 103–111, 2008.
[24] V. Selvaraj and M. Alagar, "Analytical detection and biological assay of antileukemic drug 5-fluorouracil using gold nanoparticles as probe," Int. J. Pharm., vol. 337, pp. 275–281, 2007.
[25] D. Baskic et al., "Analysis of cyclohex-imide-induced apoptosis in human leukocytes: fluorescence microscopy using annexin V/propidium iodide versus acridin orange/ethidium bromide," Cell Biol. Int., vol. 30, pp. 924–932, 2006.
[26] D. Ribble et al., "A simple technique for quantifying apoptosis in 96-well plates," BMC Biotechnol., vol. 5, pp. 12, 2005.
[27] C. Kuropkat et al., "Severe cardiotoxicity during 5-fluorouracil chemotherapy: a case and literature report," Am. J. Clin. Oncol., vol. 22, pp. 466–470, 1999.
[28] P. M. De Angelis et al., "Cellular response to 5-fluorouracil(5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery," Mol. Cancer, vol. 5, pp. 20–45, 2006.
[29] Y. C. He et al., "Toxicities and therapeutic effect of 5-fluorouracil controlled release implant on tumor-bearing rats," World J. Gastroenterol., vol. 9, pp. 1795–1798, 2003.
[30] E. Fournier et al., "Development of novel 5-FU-loaded poly (methylidene malonate 2.1. 2)-based microspheres for the treatment of brain cancers," Eur. J. Pharm. Biopharm., vol. 57, pp. 189–197, 2004.
[31] E. Fournier et al., "Therapeutic effectiveness of novel 5 fluorouracil loaded poly (methylidene malonate 2.1. 2) based microspheres on F98 glioma bearing rats," Cancer, vol. 97, pp. 2822–2829, 2003.
[32] S. Desgouilles et al., "The design of nanoparticles obtained by solvent evaporation: a comprehensive study," Langmuir, vol. 19, pp. 9504–9510, 2003.
[33] A. Jain and S. K. Jain, "In vitro and cell uptake studies for targeting of ligand anchored nanoparticles for colon tumors," Eur. J. Pharm. Sci., vol. 35, pp. 404–416, 2008.